Despite major product launches from diabetes rivals last year, Abbott’s diabetes unit brought in $1.8bn total Q1 sales to ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...

Continuous glucose monitoring devices could overstate blood sugar levels, with a study revealing inconsistencies in readings compared with traditional methods.

Medical device maker Abbott Laboratories maintained its annual profit forecast on Wednesday and said it expected the U.S.

The battle to claim the continuous glucose monitor with the longest wear time continues with Dexcom Inc.’s G7 15 Day continuous glucose monitor gaining U.S. FDA clearance on April 10 for adults with ...

Once-weekly basal insulin combined with an intermittently scanned continuous glucose monitor reduced HbA1c and improved time ...

Investing.com - Abbott Laboratories (NYSE:ABT) has backed its full-year financial guidance despite noting a period of ...

Guidance: Abbott reaffirms full-year 2025 adjusted EPS of $5.05-$5.25 versus a consensus of $5.15, with organic sales growth ...

Libre Drives Diabetes Care: Abbott’s Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Abbott’s continuous glucose monitoring (CGM) device, the FreeStyle Libre, has been integrated with Glooko’s digital platform for diabetes management. The integration is available for ...

As per Vantage Market Research, the Global Hba1c Testing Device Market has been significantly growing over the years due to ...